## BSX: Boston Scientific Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.2% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($92.14)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Boston Scientific Corp. stock: quiet tape, loud expectations as Wall Street leans bullish**
- Source: AD HOC NEWS | 20251229T190842 | Bullish | Relevance: 100%
- Boston Scientific Corp. stock has remained in a narrow range recently, showcasing a high-conviction growth story in minimally invasive medicine, even as it trades near record highs. Despite recent minor pullbacks, analysts maintain a strong bullish outlook due to the company's robust innovation pipeline and strategic focus on high-growth segments in cardiovascular and neuromodulation therapies. Investors are watching for continued procedure growth and effective integration of acquisitions to further propel the stock.

**2. Sowell Financial Services LLC Sells 28,806 Shares of Boston Scientific Corporation $BSX**
- Source: MarketBeat | 20251229T110025 | Neutral | Relevance: 100%
- Sowell Financial Services LLC significantly reduced its stake in Boston Scientific Corporation by selling 28,806 shares in Q3, now owning 27,546 shares valued at approximately $2.69 million. Despite this, Boston Scientific exceeded Q3 earnings and revenue estimates and set strong FY2025 guidance. The company maintains high institutional ownership and a consensus "Buy" rating from analysts with an average target price of $124.85.

**3. Boston Scientific Corporation $BSX Stock Position Lessened by Ethic Inc.**
- Source: MarketBeat | 20251229T095159 | Neutral | Relevance: 100%
- Ethic Inc. reduced its stake in Boston Scientific Corporation by 10.7% in the third quarter, while other institutional investors have shown varied activity, some increasing their holdings. Boston Scientific reported strong Q3 earnings, surpassing analyst estimates with $0.75 EPS and revenues of $5.07 billion, and provided optimistic guidance for FY2025. Despite this, company insiders, including two EVPs, have been net sellers of the stock in the last 90 days.

**4. U.S. Embolic Protection Devices Market and Competition Analysis, 2025-2033, Featuring Abbott Laboratories, Allium Medical Solutions, Boston Scientific, Cardinal Health and More**
- Source: Yahoo Finance | 20251229T162823 | Somewhat-Bullish | Relevance: 85%
- The U.S. Embolic Protection Device Market is projected to grow from US$360 million in 2024 to US$650 million by 2033, with a CAGR of 6.96%. This growth is primarily driven by the increasing prevalence of cardiovascular diseases, an aging population, and technological advancements in device design. Key challenges include the high cost of devices and complexities in reimbursement, as well as the need for highly skilled operators to properly use these devices.

**5. Collagen Meniscus Implant Market Forecast: Unveiling High-Growth Business Opportunities for the New Year | Zimmer Biomet Holdings, Inc., RTI Surgical Holdings, Inc.**
- Source: openPR.com | 20251229T070909 | Somewhat-Bullish | Relevance: 74%
- The Collagen Meniscus Implant Market is projected for strong growth from 2025 to 2032 due to rising demand, expanding applications, and technological advancements. A new report by Coherent Market Insights details market size, revenue trends, key growth factors, and competitive landscapes, offering actionable insights for data-driven decisions. Leading companies like Zimmer Biomet Holdings Inc. and RTI Surgical Holdings Inc. are highlighted in this comprehensive analysis.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $120 | $130 | -8% |
| 2025-12-17 | Canaccord Genui | $131 | $132 | -1% |
| 2025-12-17 | RBC Capital | $130 | $125 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Buy |
| 2025-12-17 | Canaccord Genui | main | Buy |
| 2025-12-17 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 3 ($1.31M) |
| Sells | 9 ($2.57M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 9.8% (-1.0%)
- Vanguard Group Inc: 9.3% (+0.8%)
- FMR, LLC: 6.7% (-8.2%)
- State Street Corpora: 4.4% (-0.4%)
- JPMORGAN CHASE & CO: 3.8% (+120.8%)

### Key Risks

1. Long-term trend broken: trading 5.1% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.94 indicates undervaluation relative to growth. Balance sheet: $2.6B free cash flow. Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $142.0B |
| Beta | 0.67 |
| 52W Range | $85.98 - $109.50 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.94 |
| Forward P/E | 27.6 |
| Current P/E | 31.6 |
| YoY Growth | 14.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.1% to -0.2% (-2.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.2pp (needs >3.0% for momentum thesis). Below SMA200 (0.95x), long-term trend not supportive. RSI neutral at 47. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.19% (CS: 60) | Neutral |
| RSI_14 | 47.2 | Neutral |
| MACD Histogram | 0.38 | Bullish |
| vs SMA20 | 1.003x | Above |
| vs SMA50 | 0.972x | Below |
| vs SMA200 | 0.949x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $95.78
- **Stop Loss:** $92.14 (3.8% risk)
- **Target:** $99.42 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 379
- **Position Value:** $36,300.62
- **Portfolio %:** 36.30%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-02-04 (Est: $0.78)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.71 | $0.75 | +5.1% |
| 2025Q2 | $0.73 | $0.75 | +3.4% |
| 2025Q1 | $0.67 | $0.75 | +11.5% |
| 2024Q4 | $0.66 | $0.70 | +6.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*